KR20210061350A - 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 - Google Patents

길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 Download PDF

Info

Publication number
KR20210061350A
KR20210061350A KR1020217008246A KR20217008246A KR20210061350A KR 20210061350 A KR20210061350 A KR 20210061350A KR 1020217008246 A KR1020217008246 A KR 1020217008246A KR 20217008246 A KR20217008246 A KR 20217008246A KR 20210061350 A KR20210061350 A KR 20210061350A
Authority
KR
South Korea
Prior art keywords
amino acid
antigen
acid sequence
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217008246A
Other languages
English (en)
Korean (ko)
Inventor
데니스 엘. 파우스트맨
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Priority to KR1020257040897A priority Critical patent/KR20260004528A/ko
Publication of KR20210061350A publication Critical patent/KR20210061350A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217008246A 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 Ceased KR20210061350A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257040897A KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765284P 2018-08-20 2018-08-20
US62/765,284 2018-08-20
PCT/US2019/047330 WO2020041361A1 (en) 2018-08-20 2019-08-20 Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257040897A Division KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Publications (1)

Publication Number Publication Date
KR20210061350A true KR20210061350A (ko) 2021-05-27

Family

ID=69591189

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217008246A Ceased KR20210061350A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드
KR1020257040897A Pending KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257040897A Pending KR20260004528A (ko) 2018-08-20 2019-08-20 길항성 항-종양 괴사 인자 수용체 수퍼패밀리 폴리펩티드

Country Status (7)

Country Link
US (2) US20210340268A1 (https=)
EP (1) EP3840782A4 (https=)
JP (2) JP7713880B2 (https=)
KR (2) KR20210061350A (https=)
CN (1) CN112955179A (https=)
CA (1) CA3109954A1 (https=)
WO (1) WO2020041361A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936137A1 (en) * 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
KR102669985B1 (ko) 2015-06-30 2024-05-29 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CN112955179A (zh) * 2018-08-20 2021-06-11 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族多肽
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
EP4149627A4 (en) * 2020-05-14 2024-05-29 The General Hospital Corporation POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
TWI878554B (zh) 2020-06-12 2025-04-01 大陸商南京維立志博生物科技股份有限公司 結合ｔｎｆｒ２的抗體及其用途
CN112159818B (zh) * 2020-08-20 2023-02-21 山东兴瑞生物科技有限公司 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法
US20240101693A1 (en) * 2021-01-21 2024-03-28 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN117858893A (zh) * 2021-06-30 2024-04-09 盛禾(中国)生物制药有限公司 一种抗tnfr2单域抗体及其制备方法和应用
CN116334768A (zh) * 2022-07-14 2023-06-27 上海肽盛医药有限公司 一种结构多样的多肽库及其构建方法和应用
WO2024219994A1 (ru) * 2023-04-16 2024-10-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CN1771055A (zh) * 2002-09-05 2006-05-10 免疫医疗公司 通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP5898082B2 (ja) * 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
AU2015237864B2 (en) * 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
WO2016094309A1 (en) * 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
CA3004830A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US11859002B2 (en) * 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
BR112019001206A2 (pt) * 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
WO2018031400A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG10201912565QA (en) * 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
WO2018092907A1 (ja) * 2016-11-21 2018-05-24 国立研究開発法人医薬基盤・健康・栄養研究所 エピトープ均質化抗体パネル、ならびにその作製方法および利用
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
CN112955179A (zh) * 2018-08-20 2021-06-11 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族多肽

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936137A1 (en) * 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
US11844814B2 (en) 2013-02-07 2023-12-19 The General Hospital Corporation Methods for expansion or depletion of T-regulatory cells
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies

Also Published As

Publication number Publication date
WO2020041361A1 (en) 2020-02-27
US20230295326A1 (en) 2023-09-21
EP3840782A1 (en) 2021-06-30
US20210340268A1 (en) 2021-11-04
CA3109954A1 (en) 2020-02-27
CN112955179A (zh) 2021-06-11
JP2021534757A (ja) 2021-12-16
EP3840782A4 (en) 2022-06-08
AU2019324134A1 (en) 2021-04-15
JP2025118591A (ja) 2025-08-13
KR20260004528A (ko) 2026-01-08
JP7713880B2 (ja) 2025-07-28

Similar Documents

Publication Publication Date Title
US20250066494A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US20240270860A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20230295326A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US20250051469A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20220348645A1 (en) Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
US20240101693A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
AU2019324134B2 (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
WO2025122817A1 (en) Antagonistic cd40 antibodies
HK40096809A (zh) 拮抗性抗肿瘤坏死因子受体超家族抗体
HK40104763A (zh) 拮抗性抗肿瘤坏死因子受体超家族抗体
HK40050964A (en) Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104